<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628208</url>
  </required_header>
  <id_info>
    <org_study_id>VNV-00635</org_study_id>
    <nct_id>NCT04628208</nct_id>
  </id_info>
  <brief_title>Clinical Study Spartan COVID-19 V2 System (Canada Alternate)</brief_title>
  <official_title>Assess the Performance of Spartan COVID-19 V2 System in a Clinical Setting in Comparison to a Laboratory (Standard of Care (SOC)) PCR Method (Canada Alternate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spartan Bioscience Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spartan Bioscience Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentre prospective study will enroll a sufficient number of patients to afford&#xD;
      approximately 30 positives and &gt; 30 negatives (as determined by the SOC - Comparator method)&#xD;
      in the United States and/or Canada. One to three sites in the Canada will participate over an&#xD;
      approximate 6-week enrolment period. The actual enrolment period will be dependent upon&#xD;
      prevalence of Covid-19, and site set up. Once positives sample size is achieved, expected&#xD;
      SARC-CoV-2 negative subjects will be permitted.&#xD;
&#xD;
      Once subjects are consented and recruited for the study, up to three (3) study-specific&#xD;
      nasopharyngeal samples for each patient will be collected by trained operators at the&#xD;
      clinical site: a single SOC swab, and two (2) Spartan swabs where the second swab is optional&#xD;
      and used when the first Spartan swab test does not produce a positive or negative result&#xD;
      (&quot;inconclusive&quot;).&#xD;
&#xD;
      The first swab sample will be tested at the clinical site according to standard of care&#xD;
      protocols currently in place for the sites' nasopharyngeal swab-based SARS-CoV-2 RT-PCR&#xD;
      testing. The second nasopharyngeal sample will be tested at the site using the Spartan&#xD;
      COVID-19 v2 System. A third, optional nasopharyngeal sample, if collected, will be tested&#xD;
      using the Spartan COVID-19 v2 System only when the test conducted with the second&#xD;
      nasopharyngeal swab does not produce a positive or negative result.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Agreement between SOC test and Spartan COVID-19 test</measure>
    <time_frame>24 hours</time_frame>
    <description>Overall percent agreement between the test results generated by the Spartan COVID-19 v2 System and the nasopharyngeal swab-based SARS-Cov-2 test currently in use at the clinical site (SOC test)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Negative for COVID-19</arm_group_label>
    <description>Subject determined to be negative for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive for COVID-19</arm_group_label>
    <description>Subject determined to be positive for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Spartan COVID-19 v2 System</intervention_name>
    <description>A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.</description>
    <arm_group_label>Negative for COVID-19</arm_group_label>
    <arm_group_label>Positive for COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects presenting to clinical study sites with symptoms of SARS-CoV-2 or suspected of&#xD;
        SARS-Cov-2 infection by a healthcare provider&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected SARS-CoV-2 infection by a healthcare provider, and whose first symptoms&#xD;
             presented ≤ 7 days of onset; or&#xD;
&#xD;
          -  Suspected SARS-CoV-2 infection from the same household of a person who tested positive&#xD;
             for SARS-CoV-2 using an authorized test; or&#xD;
&#xD;
          -  Known positive SARS-CoV-2 infection using an authorized test, and whose first symptoms&#xD;
             presented ≤ 7 days of onset; or&#xD;
&#xD;
          -  Expected negative SARS-CoV-2 infection - individuals with no symptoms or a recent&#xD;
             negative result by an authorized test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vulnerable populations (e.g., women with pregnancy, institutionalized individual) as&#xD;
             deemed inappropriate for study by the site investigator&#xD;
&#xD;
          -  Individuals with self-reported nosebleed within 24 hours of presentation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tara Linseman</last_name>
    <phone>[613] 228-775</phone>
    <phone_ext>739</phone_ext>
    <email>tara.linseman@sparatnbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ottawa hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poppy MacPhee</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>14646</phone_ext>
      <email>pmacphee@ottawaheart.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

